Nephros, Inc. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 15, 2024. This annual filing reports full-year results, not a standalone fourth quarter. Nephros develops and sells water filtration products for medical and commercial markets.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $14.238 million | $9.975 million |
| Gross profit / margin | $8.405 million / 59% | $4.731 million / 47% |
| Operating loss | $(1.593) million | $(4.335) million |
| Net loss | $(1.575) million | $(7.106) million |
| Net loss attributable to Nephros shareholders | $(1.575) million | $(7.382) million |
| Basic and diluted loss per share attributable to shareholders | $(0.15) | $(0.73) |
| Cash from operating activities | $0.827 million | $(3.234) million |
| Cash and cash equivalents at year-end | $4.307 million | $3.634 million |
Revenue rose 43%, driven by sales and commercial distribution efforts. Gross margin returned to the company’s stated 55%–60% target range; 2022 was affected by expired-inventory write-downs and elevated shipping costs. SG&A increased 17% to $8.911 million, while R&D fell 30% to $0.873 million, largely reflecting SRP’s wind-down. 2022 included a $2.829 million loss from discontinued PDS operations; 2023 reported none.
At December 31, 2023, current assets were $8.405 million, current liabilities $2.113 million, and working capital $6.292 million. Stockholders’ equity was $8.358 million, versus $8.881 million a year earlier. The secured note was paid off during 2023; the company reported no secured-note balance at year-end. Lease liabilities totaled approximately $1.836 million, including finance leases.
Material changes and notable events
- SRP, the HDF development subsidiary, was dissolved in 2023 after failing to secure a commercial partner or additional financing. It assigned its remaining assets, including HDF2 intellectual property, to Nephros in satisfaction of an approximately $1.5 million loan. Nephros says it has no current HDF plans but may reassess later.
- Nephros entered a new exclusive license and supply agreement with Medica in December 2023, extending the arrangement through December 31, 2028. Minimum purchases increase from €4.208 million in 2024 to €5.750 million in 2028; the company says it met its 2023 minimum.
- Two customers represented 34% of 2023 revenue, compared with 36% in 2022. The largest customer represented 23% of 2023 revenue.
- Common shares issued and outstanding were 10,543,675 as of March 6, 2024. Wexford Capital beneficially owned approximately 35% as of March 1, 2024, and Wexford, directors, and executive officers collectively approximately 37.5%.
Outlook, risks, and contingencies
Management expects continued operating losses until sales and/or licensing revenue support profitability. It believes cash resources and anticipated revenue will fund the current operating plan for at least 12 months from the financial statements’ issuance date, based in part on positive 2023 operating cash flow. This is not a guarantee; management says weaker-than-expected results could require further discretionary cost reductions, including headcount and R&D cuts. No specific revenue or earnings guidance is provided.
- Key risks include sustaining sales growth and customer reorders, achieving market acceptance, competition, and dependence on distributors and a limited number of manufacturers.
- A single-source supplier provides proprietary filter material for several medical products. Medica purchase commitments and reliance on the supplier expose the company to supply, cost, and execution risks.
- Product liability insurance is $3 million; claims exceeding coverage could materially affect the company. Medical-device regulatory compliance, quality controls, and obtaining future approvals also remain risks.
- Nephros reported an accumulated deficit of $144.4 million and a history of operating losses. Two customers accounted for 34% of revenue, and sales growth may not continue.
- The company reported no material pending legal proceedings. Its auditor issued an unqualified opinion on the financial statements; management concluded disclosure controls and internal control over financial reporting were effective. Inventory valuation was identified as a critical audit matter due to management judgment in reserving for excess and obsolete inventory.
Most important facts for investors to verify
- Whether revenue growth and 59% gross margin persist, and whether the company can reach profitability without additional financing.
- Cash burn, working-capital trends, and the scale and timing of Medica’s contractual minimum purchases relative to sales and available cash.
- Customer concentration, distributor performance, and the status of the exclusive commercial distribution relationship.
- Supplier continuity, product quality and regulatory status, and the adequacy of product-liability coverage.
- Potential dilution from equity awards and the influence of Wexford’s significant voting stake.